Exploratory phase 2a RCT in 48 patients with cirrhosis and prior overt HE: oral YAQ007 lowered ammonia within groups by day 5 at 4 g twice and three times daily vs baseline; no clear dose-response. Adverse events 55.6% vs 41.7% with rifaximin.
RCTn = 48 patients
Ballester et al. A randomized, open-label, phase 2a study to assess the safety, pharmacodynamics, and pharmacokinetics of YAQ007 versus rifaximin in cirrhosis